Evidence map›Paper›PMID 28499416›Full record

ArticleSystematic reviews2017

Cardioprotective potential of N-acetyl cysteine against hyperglycaemia-induced oxidative damage: a protocol for a systematic review.

Phiwayinkosi V Dludla, Bongani B Nkambule, Stephanie C Dias, Rabia Johnson

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Systematic reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04562597 (A Pilot Trial to Determine the Effective Dose of N-acetylcysteine for Opioid Reduction in Patients Undergoing Spine Surgery.), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04562597 phase1 / phase2completednot on this mapstarted 2021, after this paper: background citation

A Pilot Trial to Determine the Effective Dose of N-acetylcysteine for Opioid Reduction in Patients Undergoing Spine Surgery.

TypeinterventionalSponsorMedical University of South CarolinaRan2021 to 2022Enrolled50ConditionsSurgeryArmsDose Response Curve Placebo, Dose Response Curve N-acetylcysteine 50 mg/kg, Dose Response Curve N-acetylcysteine 100 mg/kg, Dose Response Curve N-acetylcysteine 150 mg/kg, Opioid Reduction with Optimal N-acetylcysteine Dose
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. MicroRNA and ROS Crosstalk in Cardiac and Pulmonary Diseases.International journal of molecular sciences · 2020
    Review
  8. Review
  9. Medical and Dietary Uses of N-Acetylcysteine.Antioxidants (Basel, Switzerland) · 2019
    Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Phiwayinkosi V DludlaBiomedical Research and Innovation Platform (BRIP), Medical Research Council, Francie van Zijl Drive, P.O. Box 19070, Tygerberg, 7505, South Africa. pdludla@mrc.ac.za.
Bongani B NkambuleSchool of Laboratory Medicine and Medical Sciences (SLMMS), College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
Stephanie C DiasBiomedical Research and Innovation Platform (BRIP), Medical Research Council, Francie van Zijl Drive, P.O. Box 19070, Tygerberg, 7505, South Africa.
Rabia JohnsonBiomedical Research and Innovation Platform (BRIP), Medical Research Council, Francie van Zijl Drive, P.O. Box 19070, Tygerberg, 7505, South Africa.
South African Medical Research Council · ZAUniversity of KwaZulu-Natal · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHyperglycaemia-induced oxidative damage is a well-established factor implicated in the development of diabetic cardiomyopathy (DCM) in diabetic individuals. Some of the well-known characteristics of DCM include increased myocardial left ventricular wall thickness and remodelling that result in reduced cardiac efficiency. To prevent this, an increasing number of pharmacological compounds such as N-acetyl cysteine (NAC) are explored for their antioxidant properties. A few studies have shown that NAC can ameliorate hyperglycaemia-induced oxidative damage within the heart. Hence, the objective of this review is to synthesise the available evidence pertaining to the cardioprotective role of NAC against hyperglycaemia-induced oxidative damage and thus prevent DCM.

methodsThis systematic review protocol will be reported in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. We will perform a comprehensive search on major databases such as EMBASE, Cochrane Library, PubMed and Google scholar for original research articles published from January 1960 to March 2017. We will only report on literature that is available in English. Two authors will independently screen for eligible studies using pre-defined criteria, and data extraction will be done in duplicate. All discrepancies will be resolved by consensus or consultation of a third reviewer. The quality of studies will be checked using Cochrane Risk of Bias Assessment Tool and The Joanna Briggs Institute (JBI) Critical Appraisal tools for non-randomised experimental studies. Heterogeneity across studies will be assessed using the Cochrane Q statistic and the inconsistency index (I DISCUSSION: Although several studies have shown that NAC can ameliorate hyperglycaemia-induced oxidative damage within the heart, this systematic review will be the first pre-registered synthesis of data to identify the cardioprotective potential of NAC against hyperglycaemia-induced oxidative damage. This result will help guide future research evaluating the cardioprotective role of NAC against DCM and better identify possible mechanisms of action for NAC to prevent oxidative damage with a diabetic heart. SYSTEMIC REVIEW REGISTRATION: PROSPERO CRD42017055851 .

Indexed as

Research DesignReview Literature as TopicAcetylcysteineCardiotonic AgentsDiabetic CardiomyopathiesHumansHyperglycemiaOxidative StressSystematic Reviews as TopicTreatment OutcomeAcetylcysteineCardiotonic AgentsCardiac protectionCardiomyopathyDiabetes mellitusN-acetyl cysteineN-acetylcysteineOxidative stress

Identifiers

PMID28499416
PMCPMC5427588
OpenAlexW2612561968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.